PTC's re-examination bid for DMD drug Translarna falls short in Europe

Thursday, PTC Therapeutics said a European Medicines Agency (EMA) committee again issued a negative opinion on renewing the Duchenne muscular dystrophy drug's authorization. The latest decision comes after a negative recommendation in September and a re-examination process.